Hypothesis

Circadian rhythms of gut microbial bile acid synthesis gate the effectiveness of psychobiotic interventions in depressive disorders.

Mechanistic Rationale

It's known that microbial communities produce bile acid metabolites such as deoxycholic acid (DCA) in a diurnal pattern that mirrors host feeding cycles. DCA activates the G‑protein‑coupled receptor TGR5 on enteroendocrine L cells, prompting release of peptide YY and serotonin that travel via vagal afferents to the nucleus tractus solitarius and subsequently modulate hypothalamic‑pituitary‑adrenal (HPA) axis activity. The gut‑brain axis communicates via vagal signaling, microbial metabolites, immune mediators, and HPA regulation gut-brain axis mechanisms. When the microbial clock is desynchronized—due to irregular diet, shift work, or antibiotic exposure—peak DCA signaling occurs at inappropriate circadian phases, blunting glucocorticoid receptor feedback and sustaining HPA hyperactivity. Psychobiotic strains that produce DCA (e.g., Clostridium scindens strains) can restore normal bile acid pools, but only if administered when the host's circadian phase aligns with the microbial production window psychobiotic trial limitations. Administering these strains outside the window yields mistimed TGR5 activation, fails to entrain the HPA axis, and explains the heterogeneous outcomes seen in current psychobiotic trials.

Testable Predictions

We're making three specific, falsifiable predictions:

1. In humans with major depressive disorder, baseline salivary cortisol curves will show a phase‑advance or phase‑delay that correlates inversely with the timing of fecal DCA peaks measured from stool samples collected across 24 h.
2. A double‑blind, crossover trial giving a DCA‑producing psychobiotic at 08:00 h (subjective morning) will reduce waking cortisol and improve MADRS scores, whereas the same dose given at 20:00 h will not differ from placebo.
3. Germ‑free mice colonized with a DCA‑producing strain and subjected to a reversed light‑dark cycle will exhibit depressive‑like behavior only when the probiotic is supplied during the animal’s subjective night; providing it during the subjective day will normalize behavior and corticosterone levels.

Experimental Design

Human arm: We're enrolling 60 medication‑free adults with MDD. We'll collect stool every 4 h for 48 h to quantify DCA via LC‑MS and obtain salivary cortisol at the same points. Participants are randomized to receive either the psychobiotic or placebo at 08:00 h or 20:00 h in a double‑blind, crossover fashion with a two‑week washout. Primary outcome: change in area under the curve (AUC) of cortisol; secondary: MADRS change at week 4. Mouse arm: We'll use C57BL/6 germ‑free mice colonized with a defined DCA‑producing Clostridium scindens strain. Half will be housed under a normal 12 h light/12 h dark cycle, half under a reversed cycle. We'll administer probiotic via gavage at ZT2 (early day) or ZT14 (early night) for 14 days. We'll measure fecal DCA, plasma corticosterone, and run sucrose preference and forced swim tests.

If the hypothesis holds, we'll see a clear interaction between administration time and microbial metabolite timing on HPA markers and depressive phenotypes; failure to observe such an interaction would falsify the claim that circadian alignment of bile acid signaling is a determinant of psychobiotic efficacy.